Asian Pacific Journal of Cancer Prevention

  • 제14권6호
  • /
  • Pages.3729-3734
  • /
  • 2013
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Overexpression of Cyclooxygenase-1 Correlates with Poor Prognosis in Renal Cell Carcinoma

  • Yu, Zu-Hu (Department of Urology, Peking University Shenzhen Hospital) ;
  • Zhang, Qiang (Department of Urology, Peking University Shenzhen Hospital) ;
  • Wang, Ya-Dong (Department of Urology, Peking University Shenzhen Hospital) ;
  • Chen, Jing (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Jiang, Zhi-Mao (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Shi, Min (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Guo, Xin (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Qin, Jie (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Cui, Guang-Hui (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Cai, Zhi-Ming (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Gui, Yao-Ting (Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center) ;
  • Lai, Yong-Qing (Department of Urology, Peking University Shenzhen Hospital)
  • 발행 : 2013.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The aim of this study was to evaluate expression of COX-1 in renal cell carcinoma (RCC) and its prognostic value. mRNA of COX-1 was detected in 42 paired RCC and adjacent normal tissues with quantitative realtime polymerase chain reaction (qRT-PCR). Expression of COX-1 was also evaluated in 196 RCC sections and 91 adjacent normal tissues with immunohistochemistry. Statistical analysis was performed to assess COX-1 expression in RCC and its prognostic significance. The results of qRT-PCR showed mRNA levels of COX-1 in RCC tissues to be significantly higher than that in adjacent normal tissues (p < 0.001). Immunohistochemical assays also revealed COX-1 to be overexpressed in RCC tissues (p < 0.001). Statistical analysis demonstrated high expression of COX-1 was correlated with tumour size (p = 0.002), pathological stage (p = 0.003), TNM stage (p = 0.003, 0.007, 0.027, respectively), and tumour recurrence (p < 0.001). Survival analysis indicated patients with high expression of COX-1 had shorter survival time (p < 0.001), and COX-1 was an independent predictor. This is the first study to reveal overexpression of COX-1 in RRC and point to use as a prognostic marker in affected patients.

키워드

참고문헌

  1. Amin MB, Tamboli P, Javidan J, et al (2002). Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol, 26, 281-91. https://doi.org/10.1097/00000478-200203000-00001
  2. Bao S, Ouyang G, Bai X, et al (2004). Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell, 5, 329-39. https://doi.org/10.1016/S1535-6108(04)00081-9
  3. Choi YD, Kim KS, Ryu S, et al (2007). Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci, 22, 305-10. https://doi.org/10.3346/jkms.2007.22.2.305
  4. Daikoku T, Wang D, Tranguch S, et al (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res, 65, 3735-44. https://doi.org/10.1158/0008-5472.CAN-04-3814
  5. Diamantopoulou K, Lazaris A, Mylona E, et al (2005). Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma. Anticancer Res, 25, 4543-9.
  6. Greene F BC, Fleming I, Fritz A, Haller D. 2002. AJCC: Cancer Staging Manual. New York: Springers-Verlag.
  7. Gupta RA, Tejada LV, Tong BJ, et al (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res, 63, 906-11.
  8. Hashimoto Y, Kondo Y, Kimura G, et al (2004). Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology, 44, 353-9. https://doi.org/10.1111/j.1365-2559.2004.01853.x
  9. Hida T, Yatabe Y, Achiwa H, et al (1998). Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res, 58, 3761-4.
  10. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  11. Jiang Z, Chu PG, Woda BA, et al (2006). Analysis of RNAbinding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol, 7, 556-64. https://doi.org/10.1016/S1470-2045(06)70732-X
  12. Liu XH, Rose DP (1996). Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res, 56, 5125-7.
  13. Mittal A, Poudel B, Pandeya DR, et al (2012). Serum amyloid a as an independent prognostic factor for renal cell carcinoma--a hospital based study from the Western region of Nepal. Asian Pac J Cancer Prev, 13, 2253-5. https://doi.org/10.7314/APJCP.2012.13.5.2253
  14. Motzer RJ, Bander NH, Nanus DM (1996). Renal-cell carcinoma. N Engl J Med, 335, 865-75. https://doi.org/10.1056/NEJM199609193351207
  15. Nogueira M, Kim HL (2008). Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol, 26, 113-24. https://doi.org/10.1016/j.urolonc.2007.03.028
  16. Patel C, Ahmed A, Ellsworth P (2012). Renal cell carcinoma: a reappraisal. Urol Nurs, 32, 182-90; quiz 91.
  17. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res, 57, 1276-80.
  18. Saussez S, Cucu DR, Decaestecker C, et al (2006). Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol, 13, 999-1009. https://doi.org/10.1245/ASO.2006.08.033
  19. Schmittgen TD, Livak KJ (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc, 3, 1101-8. https://doi.org/10.1038/nprot.2008.73
  20. Sejima T,Miyagawa I (2006). Significance of Fas expression alteration during tumor progression of renal cell carcinoma. Int J Urol, 13, 257-64. https://doi.org/10.1111/j.1442-2042.2006.01265.x
  21. Shindo T, Masumori N, Kobayashi K, et al (2013). Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable. BJU Int, 111, 941-5. https://doi.org/10.1111/j.1464-410X.2012.11771.x
  22. Shvarts O, Seligson D, Lam J, et al (2005). p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol, 173, 725-8. https://doi.org/10.1097/01.ju.0000152354.08057.2a
  23. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  24. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971). Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer, 28, 1165-77. https://doi.org/10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G
  25. Skolarikos A, Alivizatos G, Bamias A, et al (2005). Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis? Int J Urol, 12, 563-9. https://doi.org/10.1111/j.1442-2042.2005.01081.x
  26. Tatokoro M, Fujii Y, Kawakami S, et al (2011). Phase-II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci, 102, 137-43. https://doi.org/10.1111/j.1349-7006.2010.01756.x
  27. Tostain J, Li G, Gentil-Perret A,Gigante M (2010). Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer, 46, 3141-8. https://doi.org/10.1016/j.ejca.2010.07.020
  28. Tsuchiya A, Sakamoto M, Yasuda J, et al (2003). Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol, 163, 2503-12. https://doi.org/10.1016/S0002-9440(10)63605-X
  29. Wei C, Lai YQ, Li XX,Ye JX (2013a). TGF-beta-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 14, 315-20. https://doi.org/10.7314/APJCP.2013.14.1.315
  30. Wood CG (2006). Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol, 94, 264-5. https://doi.org/10.1002/jso.20448

피인용 문헌

  1. microRNA-145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma vol.10, pp.1, 2014, https://doi.org/10.3892/mmr.2014.2149
  2. Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer vol.10, pp.15, 2014, https://doi.org/10.2217/fon.14.162
  3. MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma pp.1791-3004, 2015, https://doi.org/10.3892/mmr.2015.3498
  4. MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN vol.13, pp.6, 2016, https://doi.org/10.3892/mmr.2016.5101
  5. Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1399
  6. Identification of genes associated with renal cell carcinoma using gene expression profiling analysis vol.12, pp.1, 2016, https://doi.org/10.3892/ol.2016.4573
  7. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature vol.11, pp.4, 2018, https://doi.org/10.3390/ph11040101